Biblio Discovery — Demo Discovery Service

4 hasil untuk "Martin Funovics"

Menampilkan 1–4 · 0,18 detik · RSS

  1. Artikel Jurnal

    Cytotoxicity of combinations of the pan-KRAS inhibitor BAY-293 against primary non-small lung cancer cells

    Adelina Plangger; Barbara Rath; Maximilian Hochmair dkk.

    Translational Oncology, Vol. 14 No. 12 · 2021 · Inggris · DOAJ Scopus

    KRAS is mutated in approximately 25% of Non-small Cell Lung Cancer (NSCLC) patients and first specific inhibitors showed promising responses that may be improved by concurrent interference with downstream signaling pathways. Cell lines exhibiting KRAS mutations show specific sensitivities to…

  2. Artikel Jurnal

    Nanoparticles for the Optical Imaging of Tumor selectin

    Martin Funovics; Xavier Montet; Fred Reynolds dkk.

    Neoplasia: An International Journal for Oncology Research, Vol. 7 No. 10 · 2005 · Inggris · DOAJ Scopus

    We designed a fluorescent peptide-magnetic noneparticle conjugate that images selectin expression in mouse xenograft models of Lewis lung carcinoma. (LLC) by fluorescence reflectance imaging. It was synthesized by attaching the selectin-binding peptide. (ESBP; CDSBSDITWDOLWDLMK) to a CLIO(Cy5.5)…

  3. Artikel Jurnal

    Signet Ring Cell Carcinoma of the Lung: A Diagnostic Pitfall in Pregnancy

    Sabine Danzinger; Wolfgang J. Köstler; Martin Funovics dkk.

    Case Reports in Obstetrics and Gynecology, Vol. 2019 · 2019 · Inggris · DOAJ Scopus

    Lung cancer during pregnancy represents a rare disease. In this case report, we present a patient at advanced and metastasized stage of signet ring cell carcinoma who presented in the 22nd week of gestation.

  4. Artikel Jurnal

    Cytotoxicity of combinations of the pan-KRAS SOS1 inhibitor BAY-293 against pancreatic cancer cell lines

    Adelina Plangger; Barbara Rath; Sandra Stickler dkk.

    Discover Oncology, Vol. 13 No. 1 · 2022 · Inggris · DOAJ Scopus

    Abstract KRAS is mutated in approximately 25% of cancer patients and first KRAS G12C-specific inhibitors showed promising responses. Pancreatic cancer has the highest frequency of KRAS mutations but the prevailing KRAS G12D mutation is difficult to target. Inhibition of the GTP exchange factor…